Peter Galajda, Marián Mokáň
Basal insulin analogues are used in treatment of patients with type 2 diabetes mellitus as effective possibility of intensification
of their treatment. Optimal basal insulin analogue applied once daily should supply physiological basal secretion
of insulin, to have minimally 24 hours of duration of action without peak of activity with low intra- and inter-individual
variability, low risk of hypoglycaemia and lower weight gain compared to standard NPH insulin. In the case of
new basal insulin glargin 300 U/mL (Gla-300) this characteristic of optimal basal insulin analogues was obtained by modification
of pharmacokinetic and pharmacodynamic profile. Gla-300 contains a three times more concentrated insulin
glargin with one third smaller depot volume compared to insulin glargin 100 U/ml (Gla-100) to achieve a longer duration
more than 24 hours and smaller day-to-day variability. Both insulin formulations exhibit a similar efficacy and safety
profile, but treatment by insulin Gla-300 is associated with lower risk of hypoglycaemia, mainly nocturnal and less
body weight gain compared to insulin Gla-100. So insulin Gla-300 represents a better option in intensification of treatment
of patients with type 2 diabetes mellitus than previous insulin Gla-100.